Batavia manufactures LASV vaccine candidate for IAVI who today announced the first vaccinations of their Lassa fever vaccine candidate

Batavia Biosciences would like to congratulate  IAVI  on their press release, as today they’ve announced volunteers in Monrovia, Liberia have been vaccinated with IAVI’s novel vaccine candidate against Lassa fever virus (LASV) in a Phase I clinical trial, named IAVI C102, supported by the Coalition for Epidemic Preparedness Innovations (CEPI). ‘LASV causes significant annual outbreaks […]
Batavia Biosciences - Favicon

Batavia Biosciences would like to congratulate  IAVI  on their press release, as today they’ve announced volunteers in Monrovia, Liberia have been vaccinated with IAVI’s novel vaccine candidate against Lassa fever virus (LASV) in a Phase I clinical trial, named IAVI C102, supported by the Coalition for Epidemic Preparedness Innovations (CEPI).

‘LASV causes significant annual outbreaks of an acute viral illness called  Lassa fever, which is endemic in many parts of West Africa. Outbreaks in Guinea, Liberia, Nigeria, Sierra Leone, South Africa, and Togo have resulted in nearly 6,000 suspected cases and more than 180 deaths since early 2022, according to  reports  by the World Health Organization (WHO).’

IAVI’s LASV vaccine candidate was manufactured by  Batavia  in Leiden, The Netherlands.  As a contract-development and manufacturing organization  focused on delivering sustainable, low-cost manufacturing solutions in the field of infectious disease and cancer, we intend to continue to strengthen our partnership with IAVI and continue to develop an end-to-end platform for more flexible, low-cost production of epidemic preparedness vaccines.

Congratulations to everyone involved in helping reduce human suffering from infectious diseases

Link to IAVI Press Release

Related

New Test for Rapid and Low-cost Quality Control for Polio Vaccines

Batavia Biosciences has developed a qPCR method that can specifically detect mutations that can accumulate in poliovirus strains during vaccine production. The test demonstrates a sensitivity level highly comparable to current best practices. The novel test has been accepted for publication in the international, peer-reviewed prestigious Vaccine journal.

Viral Vector Production Guide

Bringing a new viral vector-based therapy from lab to market? This resource guides you through the complexities of viral vector development, scale-up, and cGMP manufacturing.

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Thermostable viral envelope protein formulation

Maximizing protein expression